|Bid||2,864.50 x 0|
|Ask||2,866.00 x 0|
|Day's range||2,812.00 - 2,875.00|
|52-week range||2,422.50 - 3,308.50|
|Beta (5Y monthly)||0.65|
|PE ratio (TTM)||10.27|
|Earnings date||17 Feb 2021|
|Forward dividend & yield||2.16 (7.64%)|
|Ex-dividend date||08 Jul 2021|
|1y target est||3,825.26|
OrganiGram Holdings (NASDAQ: OGI) reported its fiscal second-quarter 2021 results this morning, and the stock initially dropped 12% on the report. The decline quickly eased, however, with shares trading about 2% lower than Monday's close as of 10:20 a.m. EDT. OrganiGram CEO Greg Engel noted the business was "challenged by industry dynamics, COVID-19 and staffing limitations at our facility."
Shareholders of tobacco giant British American Tobacco (NYSE: BTI) had to be happy with the month of March, as shares gained 11.6% in the period, according to data provided by S&P Global Market Intelligence. In mid-February, when the company reported its fiscal 2020 results, BAT updated investors on several aspects of its "new categories" segment. Its Vuse vapor revenue grew 85%, for example.
The stocks of several cannabis producers have more than doubled just since the start of the year, including Organigram Holdings (NASDAQ: OGI). Organigram got an added boost from news of a strategic partnership in March, helping its shares gain 14.5% in the month, according to data provided by S&P Global Market Intelligence. On March 11, news that Organigram and tobacco giant British American Tobacco (NYSE: BTI) formed a business alliance caused the stock to spike almost 40% that day.